Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Why Novo Nordisk Stock Is Sinking This Week
02:10pm, Friday, 07'th Nov 2025
Novo's third-quarter earnings and sales missed expectations. The company is losing share of the anti-obesity drug market to competitors.
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
11:49am, Friday, 07'th Nov 2025
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but
Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE
03:34am, Friday, 07'th Nov 2025
Fangzhou was named an “Outstanding Strategic Health Ecosystem Partner,” recognizing its role in advancing digital innovation in chronic disease management.
Novo Nordisk shares fall after deal with Trump to slash obesity drug prices
03:23am, Friday, 07'th Nov 2025
Shares in Novo Nordisk fell at opening on Friday, after the Wegovy-maker and rival Eli Lilly struck a deal late on Thursday with U.S. President Donald Trump to slash prices of their GLP-1 weight-loss
Lily, Novo cut prices on Wegovy and Zepbound in exchange for deal on tariffs
04:39pm, Thursday, 06'th Nov 2025
Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. Presi
Trump administration reaches deal to lower prices of obesity and diabetes drugs
03:50pm, Thursday, 06'th Nov 2025
The Trump administration has announced agreements with pharmaceutical companies Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) to reduce the cost of GLP-1 medications used to treat obesity, d
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
03:30pm, Thursday, 06'th Nov 2025
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
02:42pm, Thursday, 06'th Nov 2025
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popul
Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits
02:36pm, Thursday, 06'th Nov 2025
Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond we
A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to
Novo CEO says its bid for Metsera is higher
02:23pm, Thursday, 06'th Nov 2025
Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc. , which has sued both Metser
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
02:10pm, Thursday, 06'th Nov 2025
President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drug
Novo Nordisk expects global sales to decline by low single digits in 2026
01:23pm, Thursday, 06'th Nov 2025
Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for U.S. govern
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
01:18pm, Thursday, 06'th Nov 2025
Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its full-year sales guidance. Novo Nordisk faces challenges from the continued compounding of GLP-1 drugs and increase
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
01:01pm, Thursday, 06'th Nov 2025
Novo Nordisk has agreed with the U.S.
